Sure, I'd be happy to explain this in a simpler way!

1. **Stocks went up:**
- Imagine you have a special chocolate bar (the stock) that people really want. If more people want it and buy it from you, the price of your chocolate bar goes up! That's what happened here.

2. **Reasons for stock going up:**
- Some stocks went up because nice things were said about them by smart investors or the company itself did something good.
- For example, "REGNXBIO" told everyone it started a big test for its special medicine for Duchenne disease. People liked this news and bought more of their chocolate bars (stocks), so the price went up!
- Another stock, "Semler Scientific", went up because they decided to buy some bitcoins.

3. **Biggest movers:**
- The stocks that had the biggest increase in price are listed at the top.
- "REGNXBIO" was one of them! Their chocolate bar (stock) went up by 17%.

4. **Why did you tell me this?**
- I told you because these are some of the big changes that happened in the stock market today. People who invest money in stocks might be interested to know about these changes.

5. **What does this mean for me?**
- If you own any of these chocolate bars (stocks), your candies might be worth more now! But remember, prices can also go down, so it's always good to be careful with your money. Read from source...

Here are some potential points to address in your criticism of financial news articles, based on the provided text:

1. **Overreliance on Single Data Point**: Some articles focus solely on a single day's price movement without providing context. For instance, discussing REGENXBIO's 17% increase without mentioning its historical volatility or recent performance limits the reader's understanding.

2. **Lack of Comparative Analysis**: The article mentions multiple stocks' gains but doesn't compare them to their sector peers or the broader market. This makes it harder for readers to understand if these moves are significant or not.

3. **Inconsistent Information**: The article lists REGENXBIO's gain as both 17% and 13.2%, which might seem contradictory. Ensuring consistent information is crucial in maintaining credibility.

4. **Omission of Relevant Information**: Some important details are missing, such as:
- What the price targets before Baird's upgrade were for RGNX.
- The specific events or releases that led to the gains for DXYZ and SMLR.
- The significance of the first patient dosing in RGNX's pivotal trial.

5. **Brevity Over Clarity**: Some statements could be clearer if they provided more detail. For example, "Semler Scientific announced it acquired 215 bitcoins" would benefit from specifying why Semler made this purchase and what impact it expects to have on its business or operations.

6. **Lack of Critical Evaluation**: The article presents information but doesn't critically evaluate it. For instance, it mentions Tesla's stock gain following news about Trump's policy outlook, but it doesn't discuss why that should impact Tesla's stock price positively.

7. **Emotional Language**: Using language like "climbed", "gained", and "soared" can sometimes create a sense of urgency or excitement that might not align with a sober, analytical approach to investing.

8. **Bias**: Financial news articles can potentially exhibit bias towards specific companies, sectors, or investment strategies based on their own portfolio holdings or the interests of their parent company/organization. This is less obvious in the provided text but is a potential issue worth considering.

These points can help you critically evaluate financial news articles and ensure they provide well-rounded, relevant information for investors.

Based on the article's content, the sentiment is overwhelmingly **Bullish/Negative**:

- Bullish: The stocks mentioned in the article all experienced significant gains. This is evident with phrases like "shares climbed," "gained," and "rose." The percentages indicate substantial increases, with the lowest gain being 4%.

- Negative: While there's no explicit negative sentiment towards any of the companies or their actions, the fact that stock prices significantly increased can be seen as a negative for short-sellers or those who had previously bet against these stocks.

There's no bearish or neutral sentiment expressed in this article. The use of percentages and phrases like "soared," "jumping," etc., reinforces the positive tone.

Based on the stocks' movements you've mentioned, here are comprehensive investment recommendations along with potential risks:

1. **AMLX**
- *Recommendation*: Buy, based on Baird's upgrade to 'Outperform.'
- *Price Target*: $11 (raised from $3).
- *Risks*:
- Price targets are not guarantees of future performance.
- The 17% increase may attract short-term traders looking for quick profits, which could lead to volatility.
- As with any stock, there's a risk that the company's fundamentals or market conditions could deteriorate.

2. **RGNX**
- *Recommendation*: Buy, following the announcement of dosing the first patient in its pivotal trial for Duchenne gene therapy.
- *Price Movement*: Up 17% to $11.30 then down slightly to close at $10.90, but still up 13.2% on the day.
- *Risks*:
- Clinical trials have inherent risks of failure or delays. If the trial for Duchenne gene therapy doesn't yield positive results, the stock could drop significantly.
- Biotech stocks can be volatile due to regulatory uncertainties and market sentiment shifts.

3. **DXYZ**
- *Recommendation*: Cautious Buy. While a 16.2% gain is impressive, such moves often attract short-term traders and may not continue.
- *Risks*:
- High volatility can lead to sharp declines after periods of strong gains.
- As with any growth stock, risks include slower growth than expected or increased competition.

4. **SMLR**
- *Recommendation*: Buy (cautiously), given the significant price increase and bitcoin acquisition announcement.
- *Risk*:
- The company's investment in bitcoin subjects it to the volatility of cryptocurrencies.

5. **RCAT** & **MBLY** & **ZETA** & **AUR**
- *Recommendations*: Cautious Buy. These stocks have moved up significantly (+8.1% to +14%) and may attract short-term traders.
- *Risks*:
- High momentum can lead to sharp reversals.
- Such moves often occur on higher than average trading volumes, which can result in more significant price swings.

6. **IAG** & **TSLA** & **NIO**
- *Recommendations*: Cautious Buy. While these stocks have gained considerable ground today (+4% to +7%), some are still down significantly from their 52-week highs.
- *Risks*:
- Gold mining stocks (like IAG) can be impacted by fluctuations in gold prices and geopolitical risks.
- EV stocks like TSLA and NIO face intense competition, regulatory pressures, and supply chain challenges.